New hope for head and neck cancer patients who failed standard therapy
NCT ID NCT05044897
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 24 times
Summary
This study tests a new drug called SI-B001 in 11 adults with advanced head and neck cancer that has returned or spread and no longer responds to standard treatments like immunotherapy or chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is. Participants receive SI-B001 alone and are monitored for side effects and cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Oriental Hospital
Shanghai, Shanghai Municipality, 200000, China
-
The Affiliated Cancer Hospital of Guizhou Medical University
Guiyang, Guizhou, China
-
The Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
Conditions
Explore the condition pages connected to this study.